Amoxicillin–clavulanate

IR labeling includes susceptible bacterial lower respiratory infection, acute otitis media, sinusitis, skin/skin-structure infection and urinary tract infection, with organism-specific beta-lactamase criteria. If susceptibility shows amoxicillin alone is appropriate without beta-lactamase production, the combination should not be used. Cultures, local resistance, site and severity guide treatment.

ES-600 is labeled for recurrent/persistent acute otitis media in children 3 months–12 years weighing ≤40 kg, with antibiotic treatment for otitis in the preceding 3 months plus age ≤2 years or daycare attendance. Target organisms include S. pneumoniae with penicillin MIC ≤2 mcg/mL and beta-lactamase-producing H. influenzae/M. catarrhalis; MIC ≥4 is outside the indication. XR is labeled for community-acquired pneumonia and acute bacterial sinusitis with its specified susceptible pathogens, including selected reduced-penicillin-susceptibility pneumococci. Do not transfer IR urinary/skin indications to XR or make ES a universal pediatric substitute.

CDC advises diagnosing bacterial rather than viral rhinosinusitis and permits watchful waiting in uncomplicated cases with reliable follow-up. Amoxicillin or amoxicillin–clavulanate can be first-line when treatment is appropriate; routine antibiotics are not recommended for uncomplicated acute bronchitis or a cold. This profile supplies product-label regimens, not one duration for every infection.

Give at the start of a meal to improve clavulanate absorption and reduce gastrointestinal intolerance. Renal restrictions can override these schedules.

Under 12 weeks: 30 mg/kg/DAY in 2 doses using 125/31.25 mg per 5 mL suspension; experience with 200/28.5 in this age group is limited. At ≥12 weeks and <40 kg, the table uses product-specific ratios. The every-12-hour regimen produces less diarrhea in label studies. Selected 200/400 suspensions and chewables contain aspartame; avoid those labeled products in phenylketonuria. At ≥40 kg use adult recommendations.

For its labeled otitis population (3 months–12 years, ≤40 kg), give 90 mg/kg/DAY amoxicillin divided every 12 hours for 10 days using 600/42.9 mg per 5 mL. This supplies about 6.4 mg/kg/DAY clavulanate. Give at the start of a meal; shake and measure with an oral dosing device. ES-600 has no established adult regimen and should not replace an adult 500/125 or 875/125 tablet merely because swallowing is difficult.

Adults and pediatric patients ≥40 kg who can swallow tablets: two 1000/62.5-mg XR tablets every 12 hours (4000/250 mg daily). Label duration is 10 days for acute bacterial sinusitis and 7–10 days for community-acquired pneumonia; current disease guidance and clinical course still inform prescribing. Take at the start of a meal; avoid a high-fat meal because clavulanate absorption falls. A scored tablet may be split for swallowing, but take both halves immediately—splitting does not authorize half a prescribed dose.

Two IR 250/125 tablets do not equal one 500/125 tablet: clavulanate doubles. A 250/125 IR tablet is not a 250/62.5 chewable and must not be used in children <40 kg. ES-600 has a different ratio from 200/28.5 or 400/57 suspension; XR cannot be replaced by IR tablets solely by matching amoxicillin milligrams. IR GFR <30 mL/min: do not use 875/125. GFR 10–30: 250/125 or 500/125 every 12 hours according to severity; <10: every 24 hours. Hemodialysis: the same strength choice every 24 hours plus an additional dose during and at the end of dialysis. XR is contraindicated at CrCl <30 mL/min or in hemodialysis. No ES-specific renal schedule or universal pediatric renal algorithm is provided by these labels.

Do not use after a serious hypersensitivity reaction to this product or another beta-lactam, or after cholestatic jaundice/hepatic dysfunction previously associated with amoxicillin–clavulanate. XR additionally contraindicates CrCl <30 mL/min and hemodialysis. Existing liver impairment without that prior drug-associated injury is a caution requiring monitoring, not automatically the same contraindication.

These selected U.S. labels have no boxed warning. Serious allergy, severe skin reactions, hepatic toxicity, enterocolitis and antibiotic-associated colitis still require explicit counseling and action.

Diarrhea, nausea/vomiting, rash and candidal overgrowth are common or recognized reactions; rates depend on formulation and studied population. Rare serious reports include hepatic injury, blood-cell abnormalities, interstitial nephritis and seizures. Excess exposure can cause crystalluria or renal injury, especially with renal impairment. Suspected overdose requires stopping further doses and supportive assessment, including hydration/renal evaluation as appropriate; amoxicillin/clavulanate can be removed by hemodialysis.

Probenecid reduces renal secretion of amoxicillin and prolongs exposure; coadministration is not recommended. Oral anticoagulants can be associated with increased INR/prothrombin time: monitor and adjust anticoagulation as needed. Allopurinol increases amoxicillin-associated rash frequency; review rather than misclassifying every rash as a predictable severe allergy.

Labels warn of possibly reduced combined oral-contraceptive efficacy through altered flora. CDC U.S. MEC 2024 classifies broad-spectrum antibiotics as category 1 for combined hormonal contraception: most do not reduce effectiveness. Do not assert routine failure or obligatory backup solely from this antibiotic; vomiting/diarrhea needs contraceptive-specific advice. Amoxicillin can give false-positive urine-glucose results with copper-reduction tests; use an enzymatic glucose-oxidase method. It can also transiently alter measured pregnancy estrogen metabolites.

Current ES/XR labels report that decades of data have not established increased major-birth-defect, miscarriage or maternal risk; this does not prove absence of risk. They note increased neonatal necrotizing enterocolitis with prophylactic amoxicillin–clavulanate in a preterm prelabor-rupture-of-membranes study, so this is not an automatic obstetric prophylaxis choice. IR labels use older “only if clearly needed” pregnancy wording. Amoxicillin enters milk; monitor exposed infants for diarrhea, rash or irritability and balance feeding benefits and maternal need. ES labeling’s general pregnancy/lactation data do not establish an adult ES dose.

IR neonate/infant dosing differs because amoxicillin renal elimination is immature. ES efficacy/safety is established for its 3-month–12-year, ≤40-kg indication, not infants younger than 3 months or a general adult population. XR use requires ≥40 kg and ability to swallow tablets. Older adults may have impaired renal function even without an age-specific dose reduction; assess renal clearance and choose formulation/dose accordingly.

Amoxicillin is primarily eliminated renally. Use the IR severe-renal schedules, avoid 875/125 below GFR 30, and do not use XR with CrCl <30 or hemodialysis. ES has no established label-specific renal adjustment schedule to extrapolate. Use caution and regularly monitor hepatic function in liver impairment; any prior amoxicillin–clavulanate-associated cholestatic injury remains a contraindication.

Amoxicillin is a bactericidal beta-lactam that inhibits bacterial cell-wall synthesis. Clavulanate inhibits selected beta-lactamases, protecting amoxicillin against some enzymatic resistance. Other resistance mechanisms can remain; use pathogen/site-specific susceptibility and current guidance rather than claiming universal coverage.

Both components are absorbed orally and weakly protein bound; amoxicillin is primarily renal, while clavulanate has renal and nonrenal elimination. Conventional IR half-lives are about 1.3 hours for amoxicillin and 1 hour for clavulanate. Meal timing supports clavulanate exposure. XR prolongs amoxicillin exposure and ES changes the component ratio; matching a daily amoxicillin total alone does not preserve the same pharmacokinetics or clavulanate dose.

Before prescribing, review bacterial indication, allergy history, previous drug-related jaundice, age/weight, renal function and interacting drugs. Use cultures/local susceptibility where relevant and revise treatment when results arrive. Follow response, diarrhea/rash, hydration and signs of liver injury; monitor hepatic impairment regularly and INR with oral anticoagulants. Prolonged or complicated treatment may require reassessment of blood counts and organ function.

Take at the start of the prescribed meal, with the additional XR meal restriction. Shake liquid and use a calibrated oral device; the pharmacist should reconstitute the correct strength. Follow the prescribed indication-specific duration, do not share or save leftovers, and contact the prescriber for worsening illness. Seek urgent care for breathing difficulty, severe rash, prolonged vomiting, jaundice or severe/watery/bloody diarrhea. Do not substitute tablets, chewables, ES or XR by comparing the first strength number.

Sandoz IR 875/125 mg is a white capsule-shaped scored GGN7 tablet; NDC 0781-1852-20 is a 20-tablet bottle. Chartwell’s 400/57-mg chewable is mottled pink, oval and unscored with 93/2272; NDC 62135-105-20 is a 20-tablet bottle. ES-600 is strawberry-cream powder, 600/42.9 mg per 5 mL after preparation; NDC 81964-003-69 supplies 125 mL. Selected XR is a white oval scored bilayer “AUGMENTIN XR” tablet; NDC 81964-220-28 supplies 28. Manufacturer-specific appearance does not identify every generic.

Selected IR tablets: 250/125, 500/125 and 875/125 mg; selected suspensions: 200/28.5 and 400/57 mg per 5 mL; selected Chartwell chewables: 200/28.5 and 400/57 mg. The IR dosing sections also specify 125/31.25 and 250/62.5 suspensions and distinguish 250/62.5 chewable from the 250/125 tablet; verify the separate dispensed label rather than assuming these legacy ratio products are supplied by the representative packages. ES: 600/42.9 per 5 mL; XR: 1000/62.5 per tablet. Pediatric prescriptions use the amoxicillin component, while formulation choice determines clavulanate exposure.

Sandoz/Chartwell IR tablets, chewables and dry suspension: 20–25°C; preserve the labeled original or tight/light-resistant dispensing container. ES dry powder and XR: at or below 25°C, in original containers. Reconstituted IR/ES suspension is refrigerated, shaken before each dose and discarded after 10 days. Storage life is not a directive to prescribe a 10-day course for every infection.